Valuation: Summit Therapeutics Inc.

Market Cap 7.44B 10.16B 8.7B 8.14B 14.05B 969B 14.18B 96.02B 37.38B 489B 38.11B 37.31B 1,617B P/E 2026 *
-10.4x
P/E 2027 * -10.7x
Enterprise Value 6.97B 9.51B 8.14B 7.62B 13.16B 907B 13.28B 89.91B 35.01B 457B 35.69B 34.93B 1,514B EV / Sales 2026 *
2,382x
EV / Sales 2027 * 173x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
1 day+4.95%
1 week+4.54%
Current month+2.61%
1 month-2.20%
3 months-19.61%
6 months-17.12%
Current year-23.61%
1 week 12.22
Extreme 12.22
13.6
1 month 12.07
Extreme 12.07
15.75
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
30.05
3 years 1.52
Extreme 1.52
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 54 24/07/2022
Chief Executive Officer 81 31/03/2020
Director of Finance/CFO 48 01/04/2024
Director TitleAgeSince
Chairman 81 31/01/2020
Director/Board Member 48 30/11/2019
Director/Board Member 54 10/11/2020
Date Insider Type Main position Quantity % Market Cap.
08/01/26 Free

Controller/Auditor

30,000 0.0040%
02/01/26 Free

Director

42,180 0.0057%
02/01/26 Free

Chief Executive Officer

11,232 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
+4.95%+4.54%-49.01%+650.56% 10.16B
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.74%+2.81%+55.45%+88.75% 63.06B
+1.09%+24.51%+2.86%-4.20% 28.34B
-0.07%-3.45%-6.06%+464.93% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.37%+39.87%-15.08% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+3.98%+8.41%+46.83%+160.78% 13.52B
Average +2.75%+3.51%+50.59%+243.80% 29.15B
Weighted average by Cap. +2.61%+2.83%+55.57%+175.14%

Financials

2026 *2027 *
Net sales 2.93M 3.99M 3.42M 3.2M 5.53M 381M 5.57M 37.75M 14.7M 192M 14.98M 14.67M 636M 41.79M 57.03M 48.83M 45.69M 78.9M 5.44B 79.6M 539M 210M 2.74B 214M 209M 9.08B
Net income -692M -945M -809M -757M -1.31B -90.14B -1.32B -8.93B -3.48B -45.45B -3.55B -3.47B -150B -733M -1B -856M -801M -1.38B -95.38B -1.4B -9.45B -3.68B -48.09B -3.75B -3.67B -159B
Net Debt -474M -646M -553M -518M -894M -61.65B -902M -6.11B -2.38B -31.08B -2.42B -2.37B -103B -202M -276M -236M -221M -382M -26.33B -385M -2.61B -1.02B -13.28B -1.04B -1.01B -43.95B
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
25/08/26 US$13.36 +4.95% 6,258,542
24/08/26 US$12.73 -3.27% 4,390,696
21/08/26 US$13.16 +5.87% 7,074,307
20/08/26 US$12.43 -5.19% 6,568,692
19/08/26 US$13.11 +2.26% 5,431,233
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
9.331GBP
Average target price
21.10GBP
Spread / Average Target
+126.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock